Project Grant R21AG087381
Award Date
6/1/25
Completion Date
5/31/26
Dollars Obligated
$429K
Federal Agency
National Institute on Aging
Federal Grant Program
93.866
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,104,254 to the HudsonAlpha Institute for Biotechnology to identify transcription factors that regulate the expression of the MAPT gene, which is associated with neurodegenerative diseases like Alzheimer's. The key objectives are to: 1) Use CRISPR-based screens to find transcription factors that can modulate MAPT transcription, 2) Determine which trans-regulatory elements directly interact...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $320,000 will fund a study on alternative polyadenylation (APA) regulation in Alzheimer's disease (AD). The research, conducted by the University of Texas Medical Branch at Galveston, aims to comprehensively profile APA transcripts and gene expression in neurons expressing wild-type and mutant tau proteins. Specifically, the study will leverage the Poly(A)-ClickSeq (PAC-Seq)...
This $1,859,444 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research on the role of the lipid sulfatide in the development of tau pathology in Alzheimer's disease and related dementias (ADRD). The primary awardee, the University of Texas Health Science Center at San Antonio, will conduct extensive investigations to determine if sulfatide deficiency leads to increased tau phosphorylation, accumulation, and aggregation in oligodendrocytes. The...
The National Institute on Aging (NIA) awarded a $763,922 Project Grant under the Aging Research federal grant program (CFDA 93.866) to The Leland Stanford Junior University. The 5-year grant, with a start date of June 1, 2025 and an end date of April 30, 2030, will fund research to investigate the mechanism by which abnormal tau protein interacts with mitochondrial dysfunction and contributes to the development of age-related neurodegenerative diseases like Alzheimer's, Parkinson's, and...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $757,027 to the University of Washington to support research on the synergistic relationship between tau and TDP-43 proteins in Alzheimer's disease (AD). The award period is from January 1, 2025 to December 31, 2029. The key objectives are to: 1) further investigate the mechanistic pathways by which tau and TDP-43 may interact to exacerbate proteotoxicity in AD, focusing on the lysosomal...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $4,276,054 to The Regents of the University of California, San Francisco (UCSF) to conduct research on the selective vulnerability of genes, cells, and neural networks in mouse tauopathy models of Alzheimer's disease (AD). The project aims to develop quantitative mathematical models to test hypotheses regarding the selective vulnerability of certain brain regions and cell types to the...
This National Institute on Aging (NIA) Project Grant award under the Aging Research program (CFDA 93.866) provides $104,164.00 to Emory University to explore the role of the TMEM106B protein in neurodegeneration. The key objectives are to: 1) determine the interaction between TMEM106B and the C9ORF72 repeat expansion, which is linked to frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS); and 2) investigate the toxicity of TMEM106B protein aggregates and their impact on...
This federal Project Grant award for $310,000 from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research at Texas Tech University Health Sciences Center (TTUHSC) to examine the role of alternative polyadenylation (APA) of mRNAs in the development and progression of Alzheimer's disease (AD). The key goals are to: 1) Identify APA genes and pathways associated with AD pathology using computational analysis of existing single-cell RNA sequencing datasets, and 2)...
This federal Project Grant award of $1,118,700.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) to New York University School of Medicine will support research to elucidate the role of pathological tau protein in disrupting endosomal microautophagy (EMI), a critical protein degradation pathway affected in Alzheimer's disease. The research aims to determine which components of the EMI pathway are most vulnerable to tau pathology and whether restoring EMI function can...
This Project Grant award of $436,150 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to better understand mitochondrial dysfunction in Alzheimer's disease (AD). The principal investigator at the University of Illinois will investigate how the E3 ubiquitin ligase NEDD4L regulates mitochondrial proteins, such as MFN2, and how dephosphorylation of NEDD4L contributes to impaired mitochondrial function and neurodegeneration in a familial AD mouse model. The...